Abstract | PURPOSE: Pharmacological therapy is typically the first-line treatment for patients with benign prostatic hyperplasia (BPH). We carried out a systematic review and meta-analysis to assess the efficacy and safety of silodosin for treating BPH. METHODS: A literature review was performed to identify all published randomized placebo-controlled trials (RCT) of silodosin for the treatment of BPH. The search included the following databases: PUBMED, EMBASE, and the Cochrane Controlled Trail Register of Controlled Trials. The reference lists of retrieved studies were also investigated. A systematic review and meta-analysis were conducted. RESULTS: Four publications involving a total of 2,543 patients were used in the analysis, including 3 RCTs that compared silodosin with placebo and 3 RCTs that compared silodosin with tamsulosin. We found that silodosin was effective in treating BPH in our meta-analysis. Total international prostate symptom score (IPSS) (P=0.92 SWD=2.92 95% CI=2.19-3.65 the mean decrease of total IPSS was from 6.4 to 10.6), voiding symptom score, storage symptom score, and quality-of-life score indicated that silodosin was more effective than the placebo. Silodosin's efficacy is similar to that of tamsulosin (P=0.37 SWD=1.14 95% CI=0.18-2.11) in our meta-analysis. However, the incidence of abnormal ejaculation was higher in patients treated with tamsulosin therapy compared with the placebo (234/1128=20.74% 12/680=1.76% 6/736=0.82%). CONCLUSIONS:
|
Authors | Yuanshan Cui, Huantao Zong, Yong Zhang |
Journal | International urology and nephrology
(Int Urol Nephrol)
Vol. 44
Issue 6
Pg. 1601-9
(Dec 2012)
ISSN: 1573-2584 [Electronic] Netherlands |
PMID | 22914879
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Chemical References |
|
Topics |
- Humans
- Indoles
(adverse effects, therapeutic use)
- Male
- Prostatic Hyperplasia
(drug therapy)
- Randomized Controlled Trials as Topic
|